GET DAILY SIGNALSScholar Rock (SRRK) Q3 2026 Earnings: Key Signals Beyond the Numbers
Key Takeaways
- Scholar Rock (SRRK) is expected to report its third-quarter 2026 results in mid-November, just weeks after apitegromab's September 30, 2026, Prescription Drug User Fee Act (PDUFA) decision date.
- The company has not yet recorded product revenue, so the update will center on its net loss, operating expenses, and cash balance rather than top-line sales.
- Analysts expect another sizable quarterly loss, in line with recent quarters when losses per share ranged from roughly $0.76 to $0.90.
- Apitegromab, an investigational muscle-targeted therapy for spinal muscular atrophy (SMA), remains the core driver of the story, alongside commercial launch readiness.
- Investors will watch guidance on cash runway and spending as the company moves toward potential commercialization.
Understanding the Earnings Context
Scholar Rock is a late-stage biopharmaceutical company built around a muscle-targeted approach to treating rare neuromuscular diseases, led by apitegromab for spinal muscular atrophy (SMA). Because the company is still pre-commercial, its quarterly earnings carry unusual weight: investors are not looking for revenue growth but for signals on regulatory progress, launch readiness, and capital discipline. This report arrives against a high-stakes backdrop, with apitegromab's U.S. review timeline and European filing progressing and the company working toward a potential first commercial launch. The financials themselves—mainly a net loss and operating expenses—matter primarily as a gauge of how much cash the company is spending as it approaches commercialization. I also checked this using Tickeron's AI Screener to see how the stock compares to others in the industry.
What Analysts Are Expecting
Scholar Rock has not yet generated product revenue, and no top-line sales are expected for the third quarter of 2026. Instead, the report will be judged on the net loss and the trajectory of operating expenses. In the second quarter of 2026, the company posted a net loss of $0.84 per share, in line with the consensus estimate, while the first quarter came in at $0.83 per share versus a roughly $0.80 consensus. Recent quarterly losses have ranged from about $0.76 to $0.90 per share, and analysts anticipate a comparable figure for the third quarter.
Key metrics to watch include research and development (R&D) expense, general and administrative (G&A) expense, and stock-based compensation, which has been a recurring non-cash component of results. The cash position is equally important: Scholar Rock ended the second quarter of 2026 with approximately $492 million in cash, cash equivalents, and marketable securities.
The shares have historically reacted more to regulatory and clinical news than to the financials themselves. In November 2025, for example, the stock surged more than 20% despite a wider-than-expected loss, after management described a constructive meeting with the U.S. Food and Drug Administration (FDA) regarding the SMA program.
How the Market Might React
Sentiment heading into the third-quarter report is closely tied to apitegromab's regulatory timeline rather than the bottom line. With the PDUFA decision date having passed in late September, investors are likely to treat any commentary on approval status, manufacturing, and commercial launch as more meaningful than the earnings figure itself. Key risk factors include potential delays tied to third-party fill-finish manufacturing, the pace of European Medicines Agency (EMA) review, and the timing of reimbursement and patient access following any approval. Because the stock has shown a pattern of sharp moves on FDA and pipeline updates, the earnings call's forward-looking commentary may matter more to traders than the reported loss. From what I see, this dynamic makes the call especially worth following closely.
Looking Ahead: Key Factors to Monitor
Looking past the third-quarter print, the most important variable remains whether apitegromab clears its regulatory hurdles and reaches a commercial launch. Any update on the U.S. Biologics License Application (BLA) review and the readiness of the company's fill-finish facilities will be closely scrutinized, given that manufacturing compliance issues previously delayed the program.
Cash management is another key theme. Scholar Rock's ability to fund a launch while continuing research and development (R&D) will depend on disciplined spending and, potentially, additional financing. Management has indicated the balance sheet is intended to support operations well into 2027, but full commercialization could require further capital.
Finally, investors should monitor the broader pipeline, including the Phase 2 OPAL study in infants and toddlers with SMA, the Phase 2 FORGE study in facioscapulohumeral muscular dystrophy (FSHD), and SRK-439, a next-generation myostatin inhibitor. Progress in these programs could broaden the company's longer-term opportunity beyond its lead indication and shape how the market values the stock after this earnings event. I'm watching this closely as the story develops.
My Take on AI Tools for Biotech Research
In my view, tools like Tickeron's AI Screener help cut through the noise when evaluating pre-commercial names such as Scholar Rock (SRRK). It lets me quickly filter for technical patterns, fundamentals, and sector trends, which adds useful context around earnings events like this one without replacing deeper fundamental work.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
SRRK's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for SRRK turned positive on October 21, 2026. Looking at past instances where SRRK's MACD turned positive, the stock continued to rise in 41 of 49 cases over the following month. The odds of a continued upward trend are 84%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on SRRK as a result. In 72 of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
SRRK moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +13.30% 3-day Advance, the price is estimated to grow further. Considering data from situations where SRRK advanced for three days, in 228 of 286 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Bearish Trend Analysis
The 10-day RSI Indicator for SRRK moved out of overbought territory on November 10, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In 24 of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The 50-day moving average for SRRK moved below the 200-day moving average on November 03, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SRRK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
SRRK broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for SRRK entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 29 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 35 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. SRRK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 59 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron Valuation Rating of 79 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (22.525) is normal, around the industry mean (3.498). P/E Ratio (-14.181) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a r&d company in biotechnology
Industry Biotechnology
Advertisement